Navigation Links
Surveyed U.S. Payers Are Significantly More Likely To Reimburse Biosimilars Developed By Multinational Manufacturers Compared With Those Developed By Regional Emerging Market Players
Date:7/22/2013

EXTON, Pa., July 22, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that U.S. payer trust in specific biosimilar manufacturers could dictate which companies will be most successful in the future biosimilar market.

The Biosimilars Advisory Service report entitled U.S. and EU Payer Perspectives finds that, when considering various types of potential biosimilar manufacturers, a greater proportion of surveyed U.S. payers place a high level of trust in large pharmaceutical companies with biologics and/or biosimilars experience compared with non-pharmaceutical companies or emerging market companies.  Not only are biosimilars that are developed by well-trusted companies significantly more likely to be reimbursed, but they are also more likely to encounter significantly fewer reimbursement restrictions than the branded agent.

Interviewed European payers believe that if biosimilars are produced to high quality standards and are approved by the European Medicines Agency, then generally their concerns associated with different types of manufacturer and country of production will be addressed. The majority of surveyed U.S. payers report that approval by the U.S. Food and Drug Administration (FDA) will be sufficient to allay some of their concerns about biosimilars. Looking at the data at the class level, a smaller proportion of payers say that FDA approval will address all of their concerns for biosimilar monoclonal antibodies and fusion proteins for chronic diseases, compared with biosimilar small recombinant proteins.

"Although the majority of surveyed U.S. payers believe that biosimilars and brands are very similar to one another with only minor, non-clinically significant differences, a large group believe that they are only somewhat similar with significant or possibly significant clinical differences," s
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
2. At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizers Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures
3. Don't Forget the Payer in Your Digital Strategy: What Payers Need and Want from Pharma
4. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Show Healthcare Payers Aren’t Taking Drug Prices Laying Down
5. SentoClone International AB Significantly Strengthens its Global Patent Portfolio Covering its Clinical Stage Sentinel Node-derived CD4 T-cell Cancer Therapy
6. Consumer Survey Indicates Mouth Guards Worsen TMJ Symptoms As Often As Significantly Improving Them – Holistic Technologies
7. U of T engineering breakthrough promises significantly more efficient solar cells
8. SHL to Invest 40 Million USD in 2013 to Significantly Expand Production Facilities
9. VIC Investor Network to Significantly Accelerate Technology Company Growth
10. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
11. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... , ... Ralco is honored to announce that it is the primary sponsor ... August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the ... their daily lives. This unique exhibit also features a birthing center for fair goers ...
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... Texas (PRWEB) , ... July 30, 2015 , ... The ... and in-depth study on the current state of the global Propanol market with a ... Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative ... study of its canine osteoarthritis stem cell product, currently under development for FDA ... and will be marketed in the US by Aratana. This product, termed AT-016, ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... and mouse embryonic cell lines are useful for in ... Systems, Inc. , The Big Blue rat cell line ... useful for in vitro mutagenesis studies. These cell lines ... system,* a system for,detecting mutations from several known mutagens ...
... 96 temperature cycler , Douglas Drake ,Stratagene Cloning ... temperature cycler *,#, with Hot Top Assembly can be ... dye terminator cycle sequencing,ready reaction kit. ... oil or wax,sample overlays that hinder the loading of ...
... An Epitope Tagging Vector for Gene Expression in Mammalian ... , , Tanya Hosfield Quinn Lu ,Stratagene , ... designed for gene,expression in mammalian cells. A target gene ... FLAG epitope ,(N-terminal, ...
Cached Biology Technology:Big Blue Rodent Cell Cultures for Mutagenesis Studies 2Automated Fluorescent-Tag Cycle Sequencing 2Automated Fluorescent-Tag Cycle Sequencing 3Automated Fluorescent-Tag Cycle Sequencing 4Automated Fluorescent-Tag Cycle Sequencing 5An Epitope Tagging Vector for Gene Expression in Mammalian Cells 2An Epitope Tagging Vector for Gene Expression in Mammalian Cells 3An Epitope Tagging Vector for Gene Expression in Mammalian Cells 4An Epitope Tagging Vector for Gene Expression in Mammalian Cells 5An Epitope Tagging Vector for Gene Expression in Mammalian Cells 6
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
(Date:7/7/2015)... Conn. , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces a revised version ... this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the cards ...
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... States are markedly underestimating the changes needed to mitigate ... change because they work in ,silos, according to pioneering ... Manchester, discovered that the lack of communication between government ... differences over who is responsible for what. He ...
... fibrillation is a cardiac arrhythmia a chronic irregularity ... people in Germany. Although the condition is not acutely ... serious illnesses, such as cardiac insufficiency, stroke and dementia. ... studies, an international team of researchers, led by LMU ...
... as the "world,s aquarium," the marine ecosystems of the ... methods are depleting the sea,s habitats, creating areas that ... story "Threatened Gulf" . But, as Octavio ... Diego will describe during a presentation at the 2010 ...
Cached Biology News:Governments 'misjudging' scale of CO2 emissions 2When the heart gets out of step 2When the heart gets out of step 3Damage to threatened Gulf of California habitats can be reversed 2
... to Peroxiredoxin 1 Peroxiredoxin (Prx) ... mammalian members have been known to ... apoptosis. Many isoforms (about 50 proteins), ... acid sequence homology, particularly amino-terminal region ...
... • Heat activated ,• Eliminates ... temperature ,• Excellent specificity allows extension ... secondary structures ,• Leaves an 'A' ... modified form of GeneChoice DNA Polymerase ...
... Synuclein Synucleins are small, soluble proteins ... certain tumors. The family includes three known ... synuclein. The alpha and beta synuclein proteins ... they are seen mainly in presynaptic terminals. ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
Biology Products: